Tarsus Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 244
- Market Cap
- $1B
- Website
- http://tarsusrx.com
- Introduction
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.
Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers
- Conditions
- Demodex Blepharitis
- Interventions
- Drug: Vehicle control
- First Posted Date
- 2023-12-26
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Tarsus Pharmaceuticals, Inc.
- Target Recruit Count
- 145
- Registration Number
- NCT06182358
- Locations
- 🇺🇸
Site, Houston, Texas, United States
🇺🇸Vision Institute, Colorado Springs, Colorado, United States
Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex
- Conditions
- Meibomian Gland DysfunctionDemodex Infestation of EyelidBlepharitisDemodectic Blepharitis
- Interventions
- Drug: Vehicle of TP-03
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Tarsus Pharmaceuticals, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT06054217
- Locations
- 🇺🇸
Shultz Chang Vision, Northridge, California, United States
🇺🇸Vita Eye Clinic, Shelby, North Carolina, United States
Study of TP-04 in Participants With Papulopustular Rosacea
- Conditions
- Papulopustular Rosacea
- Interventions
- Other: Vehicle control gel
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Tarsus Pharmaceuticals, Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT05838170
- Locations
- 🇨🇦
The Centre for Clinical Trials, Oakville, Ontario, Canada
🇨🇦SKiN Centre for Dermatology, Peterborough, Ontario, Canada
🇨🇦K. Papp Clinical Research, Waterloo, Ontario, Canada
Study to Evaluate the Food Effect of TP-05 in Healthy Participants
- Conditions
- Healthy
- Interventions
- Drug: TP-05 (lotilaner oral), fasted groupDrug: TP-05 (lotilaner oral), high-fat groupDrug: TP-05 (lotilaner oral), low-fat group
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Tarsus Pharmaceuticals, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT05720364
- Locations
- 🇺🇸
Dr. Vince Clinical Research, Overland Park, Kansas, United States
Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD
- Conditions
- BlepharitisDemodex InfestationMeibomian Gland Dysfunction
- Interventions
- Drug: TP-03 Vehicle
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Tarsus Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05454956
- Locations
- 🇺🇸
Mitchell C. Shultz, MD, Northridge, California, United States
🇺🇸Silverstein Eye Center, Kansas City, Missouri, United States
🇺🇸Oculus Research, Cary, North Carolina, United States
A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05
- Conditions
- Healthy Volunteer
- Interventions
- Drug: Low Dose TP-05Drug: High Dose TP-05Drug: Placebo Comparator
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Tarsus Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05387083
- Locations
- 🇺🇸
Tufts University School of Medicine, Boston, Massachusetts, United States
A Six Week Pharmacokinetic Study of TP-03 in Healthy Subjects
- Conditions
- Healthy
- Interventions
- Drug: TP-03 (Lotilaner Ophthalmic Solution), 0.25%
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Tarsus Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05138861
- Locations
- 🇨🇦
Altasciences, Mount Royal, Quebec, Canada
A Pharmacokinetic Study of TP-05 in Healthy Subjects
- Conditions
- Healthy
- Interventions
- Drug: PlaceboDrug: TP-05 (lotilaner oral capsules)
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- Tarsus Pharmaceuticals, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT05138796
- Locations
- 🇺🇸
Altasciences, Overland Park, Kansas, United States
Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis
- First Posted Date
- 2021-03-05
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Tarsus Pharmaceuticals, Inc.
- Target Recruit Count
- 412
- Registration Number
- NCT04784091
- Locations
- 🇺🇸
Global Retina Institute, Scottsdale, Arizona, United States
🇺🇸Shultz Chang Vision, Northridge, California, United States
🇺🇸East Bay Eye Center, San Ramon, California, United States
Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis
- Conditions
- Blepharitis
- Interventions
- Drug: TP-03, 0.25%Drug: TP-03 Vehicle
- First Posted Date
- 2020-07-17
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Tarsus Pharmaceuticals, Inc.
- Target Recruit Count
- 421
- Registration Number
- NCT04475432
- Locations
- 🇺🇸
Cornea and Cataract Consultants of Arizona, Phoenix, Arizona, United States
🇺🇸Eye Research Foundation, Newport Beach, California, United States
🇺🇸Visionary Eye Institute, Newport Beach, California, United States